Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vinorelbine
Drug ID BADD_D02363
Description Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting [A32347]. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002].
Indications and Usage Not Available
Marketing Status Prescription; Discontinued
ATC Code L01CA04
DrugBank ID DB00361
KEGG ID D08680
MeSH ID D000077235
PubChem ID 5311497
TTD Drug ID D01HTL
NDC Product Code 25021-204; 45963-607
Synonyms Vinorelbine | 5'-Nor-anhydrovinblastine | 5' Nor anhydrovinblastine | KW 2307 | KW-2307 | KW2307 | Navelbine | Vinorelbine Tartrate
Chemical Information
Molecular Formula C45H54N4O8
CAS Registry Number 71486-22-1
SMILES CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N 6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombosis24.01.01.006--Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000533%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.002398%
Tonsillitis11.01.13.006; 22.07.03.0080.001066%Not Available
Tuberculosis11.04.01.0060.000533%Not Available
Tumour pain16.32.03.003--
Urinary tract infection20.08.02.001; 11.01.14.0040.000533%
Urticaria23.04.02.001; 10.01.06.001--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vestibular disorder17.02.02.008; 04.04.02.001--
Vomiting07.01.07.0030.005328%
Weight decreased13.15.01.0050.001865%
Cardiotoxicity12.03.01.007; 02.01.01.0020.000533%Not Available
Hypoacusis04.02.01.006--
Vascular pseudoaneurysm24.03.02.010; 12.02.01.0010.000533%Not Available
Neutropenic sepsis11.01.11.006; 01.02.03.0070.000695%Not Available
Ejection fraction decreased13.14.02.0030.000533%
Deep vein thrombosis24.01.02.0030.000533%Not Available
Malignant neoplasm progression16.16.01.0050.000278%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000799%Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.002664%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.000533%Not Available
Bicytopenia01.03.03.0100.000533%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000533%Not Available
Recall phenomenon12.02.06.001; 23.03.07.005--
Embolism24.01.01.009--
Haematotoxicity12.03.01.025; 01.05.01.0070.000799%Not Available
Neoplasm progression16.16.02.0050.000139%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.003730%
Demyelinating polyneuropathy17.09.04.003; 10.04.10.0070.000533%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages